Further, subtoxic doses of APE1 inhibitor III (50 nM) added to decitabine substantially decreased the surviving fraction in 1 MDS (MDS#3), 4 CMML (CMML#1–4), and 10 AML (AML#1, AML#3–5, AML#7, AML#8, AML#10, AML#11, AML#16, AML#17) cell samples (Table 1, Figure 2C,D). This evidence concerns the gene APEX1 and chronic myelomonocytic leukemia.